Bausch Health
About: Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum revenue from the Bausch + Lomb segment.
Employees: 20,700
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
17% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 30
1% more funds holding
Funds holding: 224 [Q4 2024] → 226 (+2) [Q1 2025]
0% more repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 66
2.65% less ownership
Funds ownership: 68.91% [Q4 2024] → 66.26% (-2.65%) [Q1 2025]
23% less capital invested
Capital invested by funds: $1.99B [Q4 2024] → $1.54B (-$455M) [Q1 2025]
29% less funds holding in top 10
Funds holding in top 10: 7 [Q4 2024] → 5 (-2) [Q1 2025]
73% less call options, than puts
Call options by funds: $19.6M | Put options by funds: $71.3M
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$10
67%
upside
Avg. target
$10
67%
upside
High target
$10
67%
upside
1 analyst rating
0 positive
0%
1 neutral
100%
0 negative
0%
RBC Capital Douglas Miehm | 67%upside $10 | Sector Perform Maintained | 2 May 2025 |
Financial journalist opinion
Based on 4 articles about BHC published over the past 30 days
Neutral
Business Wire
1 week ago
Bausch + Lomb Launches Blink® Nourish Lubricating Eye Drops and Blink Boost Lubricating Eye Drops in the United States
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of Blink Nourish Lubricating eye drops and Blink Boost Lubricating eye drops. Both products are preservative-free, contact-lens friendly and uniquely formulated to provide hydration and comfort for dry eyes in a multi-dose bottle. "Blink Nourish and Blink Boost deliver the same science-backed, lo.
Negative
Zacks Investment Research
2 weeks ago
Why Is Bausch (BHC) Down 13% Since Last Earnings Report?
Bausch (BHC) reported earnings 30 days ago. What's next for the stock?
Neutral
GlobeNewsWire
3 weeks ago
Facial Injectable Market Forecasts Report 2025-2030, Competitive Analysis of Key Players - Allergan, Bausch Health, Bloomage Biotechnology, and Galderma
The facial injectable market is poised for significant growth, with a rise from US$18.310 billion in 2025 to US$32.083 billion by 2030, driven by an 11.87% CAGR. Increasing emphasis on physical appearance and the popularity of minimally invasive procedures fuel demand, while the Asia-Pacific region sees rapid expansion due to urbanization and rising incomes. Key players like Allergan and Galderma lead the way. For insights and strategic opportunities, explore historical data and forecasts included in this comprehensive market report. The facial injectable market is poised for significant growth, with a rise from US$18.310 billion in 2025 to US$32.083 billion by 2030, driven by an 11.87% CAGR. Increasing emphasis on physical appearance and the popularity of minimally invasive procedures fuel demand, while the Asia-Pacific region sees rapid expansion due to urbanization and rising incomes. Key players like Allergan and Galderma lead the way. For insights and strategic opportunities, explore historical data and forecasts included in this comprehensive market report.
Neutral
Business Wire
3 weeks ago
Bausch + Lomb Launches New LUMIFY® Preservative Free Redness Reliever Eye Drops in the United States
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of LUMIFY Preservative Free redness reliever eye drops, the first and only preservative-free over-the-counter eye drops with low-dose brimonidine tartrate 0.025% that relieve redness of the eye due to minor eye irritations. “Consumers often say how amazed they are at the difference our original L.
Neutral
Accesswire
1 month ago
Bausch Health Announces 2025 Annual Meeting of Shareholder Results
LAVAL, QC / ACCESS Newswire / May 14, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced the election of the 10 directors nominated at its 2025 annual meeting of shareholders ("Annual Meeting") held on May 13, 2025. The detailed results of the vote for the election of directors are set out below: Name For Withheld Broker Non-Votes Thomas J.
Neutral
Business Wire
1 month ago
Bausch + Lomb Launches Zenlens® CHROMA HOA™ in the United States
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of Zenlens CHROMA HOA scleral contact lenses. Designed to correct advanced higher-order aberrations (HOA), this custom, wavefront-guided scleral lens technology delivers enhanced vision and improves clarity by reducing symptoms such as halos and glare. “Zenlens CHROMA HOA is a high-quality, custo.
Negative
Zacks Investment Research
1 month ago
New Strong Sell Stocks for May 13th
ALTI, AMRK and BHC have been added to the Zacks Rank #5 (Strong Sell) List on May 13, 2025.
Neutral
Business Wire
1 month ago
Bausch + Lomb Receives European CE Mark Approval for Preloaded LuxLife® Full Range of Vision Intraocular Lens
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced CE Mark approval for the LuxLife full range of vision intraocular lens (IOL). The preloaded IOL provides patients with natural, continuous vision, from distance to near. Today's announcement reinforces Bausch + Lomb's commitment to equip cataract surgeons with choices to fit the right lens to the right patient f.
Neutral
Accesswire
1 month ago
Xifaxan(R) (rifaximin) Treatment Following Overt Hepatic Encephalopathy (OHE) Hospitalization Associated with Reduced Risk of 30-Day OHE Rehospitalization
New analysis suggests efficacy of Xifaxan to mitigate OHE rehospitalizations irrespective of treatment history LAVAL, QC / ACCESS Newswire / May 6, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), today announced new data showing that people hospitalized due to overt hepatic encephalopathy (OHE) had a reduced risk of OHE-related rehospitalization within 30 days if treated with Xifaxan® (rifaximin) following hospital discharge regardless of prior treatment. These findings, based on a claims-based analysis, will be presented today at Digestive Disease Week® (DDW) 2025 in San Diego, CA.
Negative
Zacks Investment Research
1 month ago
Bausch Health Q1 Earnings and Revenues Miss Estimates, Stock Down
BHCs first-quarter 2025 adjusted earnings and revenues miss estimates. Salix performs lower than expected.
Charts implemented using Lightweight Charts™